(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R)-5-[(1R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric acid | 11048-06-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R)-5-[(1R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric acid
• CAS: 11048-06-9
• 化学式: C23H47N5O18S
• 分子量: 713.7
• InChiKey: LJRDOKAZOAKLDU-UMIPPVEZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.51
• 重原子数：
  47
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  430
• 氢给体数：
  15
• 氢受体数：
  23

文献信息

• MODULATION OF AXON DEGENERATION
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2340040B1

  公开（公告）日：2019-01-16
• Modulation of Axon Degeneration
  申请人：Watts Ryan

  公开号：US20110256150A1

  公开（公告）日：2011-10-20

  The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
• TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS
  申请人：UTI LIMITED PARTNERSHIP

  公开号：US20190262353A1

  公开（公告）日：2019-08-29

  In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neurological disease is multiple sclerosis (also referred to as “MS”).
• DESMOCOLLIN 1 INHIBITORS FOR THE PREVENTION OR TREATMENT OF ATHEROSCLEROSIS
  申请人：GENEST Jacques

  公开号：US20200129535A1

  公开（公告）日：2020-04-30

  There are provided compositions and methods for prevention or treatment of atherosclerosis and related disorders. More specifically, there are provided desmocollin 1 inhibitor compounds and pharmaceutical compositions thereof for use in the prevention or treatment of atherosclerosis and related disorders and/or for promotion of HDL biogenesis in a subject.
• US9101645B2
  申请人：——

  公开号：US9101645B2

  公开（公告）日：2015-08-11